Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
RIC Regimen for Elderly or High Comorbidity Burden Patients Receiving Haplo-HSCT
- First Posted Date
- 2018-01-26
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT03412409
- Locations
- 🇨🇳
Peking University, Institute of Hematolgoy, Beijing, China
CBA Versus FBA Conditioning Followed by Allogeneic HSCT in Treatment of High Risk and Refractory AML
- First Posted Date
- 2017-12-27
- Last Posted Date
- 2021-10-12
- Target Recruit Count
- 120
- Registration Number
- NCT03384212
- Locations
- 🇨🇳
Shanghai general hospital, Shanghai Jiaotong university school of medicine, Shanghai, Shanghai, China
CBA Versus FBA Conditioning Followed by Haploidentical Allogeneic HSCT in Treatment of High Risk and Refractory AML
- First Posted Date
- 2017-12-27
- Last Posted Date
- 2021-10-12
- Target Recruit Count
- 120
- Registration Number
- NCT03384225
- Locations
- 🇨🇳
Shanghai general hospital, Shanghai Jiaotong university school of medicine, Shanghai, Shanghai, China
A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- First Posted Date
- 2017-12-27
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 47
- Registration Number
- NCT03384654
- Locations
- 🇺🇸
Children'S Healthcare Of Atlanta/Emory Univ. Dept. Of Pediatrics, Atlanta, Georgia, United States
🇺🇸Newark Beth Israel Medical Center, Newark, New Jersey, United States
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States
Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations
- Conditions
- Interventions
- First Posted Date
- 2017-12-22
- Last Posted Date
- 2018-01-04
- Lead Sponsor
- Li Junmin
- Target Recruit Count
- 100
- Registration Number
- NCT03381781
- Locations
- 🇨🇳
Shanghai Institute of Hematology, Shanghai, China
🇨🇳Ruijin Hospital North, Shanghai, China
🇨🇳Ruijin Hospital, Shanghai, China
Haploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML Patients
- Conditions
- Interventions
- First Posted Date
- 2017-12-21
- Last Posted Date
- 2019-04-05
- Lead Sponsor
- St. Petersburg State Pavlov Medical University
- Target Recruit Count
- 16
- Registration Number
- NCT03381118
- Locations
- 🇷🇺
Boris V Afanasyev, MD, Prof., Saint Petersburg, Russian Federation
Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.
- First Posted Date
- 2017-12-20
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 301
- Registration Number
- NCT03379727
- Locations
- 🇸🇪
Novartis Investigative Site, Uppsala, Sweden
DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess
- Conditions
- Interventions
- First Posted Date
- 2017-11-29
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Shanghai Tong Ren Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT03356080
- Locations
- 🇨🇳
The center hospital of Shanghai Fengxian District, Shanghai, China
🇨🇳Fujian Medical University Union Hospital, Fuzhou, China
🇨🇳First Affiliated Hospital of Zhengzhou University., Zhengzhou, China
Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL
- First Posted Date
- 2017-11-21
- Last Posted Date
- 2022-10-20
- Lead Sponsor
- Julio Barredo, MD
- Target Recruit Count
- 6
- Registration Number
- NCT03349281
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 53
- Registration Number
- NCT03330821
- Locations
- 🇺🇸
Los Angeles County-USC Medical Center, Los Angeles, California, United States
🇺🇸University of Arizona Cancer Center - North Campus, Tucson, Arizona, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.